Primary Job Title Interim CEO & Bord of Directors Primary Organization 
Nanospectra Biosciences
Gender Male
LinkedIn View on LinkedIn
Mr. Jorden has been appointed to serve as Interim CEO with Nanospectra effective June 1, 2013.
He has extensive executive experience which includes currently serving as Executive Chairman and Executive Board Member for Cytomedix, Inc. and previously serving as Acting Chief Financial Officer for Opexa Therapeutics, Inc., Vice President of
Wealth Management for Morgan Stanley, Vice President and Chief Financial Officer for Genometrix, Inc., and Principal for Fayez Sarofim & Co.
Mr. Jorden currently serves as the Director of Cytomedix, Inc., Opexa Therapeutics, Inc., PLx Pharma, Inc., and Nanospectra Biosciences, Inc.
He holds the Chartered Financial Analyst and Certified Public Accountant designations and has extensive experience in various aspects of corporate finance and accounting for public companies including capital formation and deployment.
He holds a MBA from Kellogg School of Management at Northwestern University and a BBA from the University of Texas/Austin.
